Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pancreatic Adenocarcinoma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 37 Prostatic Neoplasms 11 Breast Neoplasms 10 Fallopian Tube Neoplasms 9 Pancreatic Neoplasms 7 Glioblastoma 6 Neoplasm Metastasis 5 Endometrial Neoplasms 5 Neoplasms 4 Lung Neoplasms 4 Glioma 4 Triple Negative Breast Neoplasms 3 Small Cell Lung Carcinoma 3 Mesothelioma 3 Cholangiocarcinoma 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Recurrence 2 Mesothelioma, Malignant 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 Brain Neoplasms 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Uterine Neoplasms 1 Urothelial Cancer 1 Unilateral Breast Neoplasms 1

Interventions

Gemcitabine 8 Albumin-Bound Paclitaxel 6 Taxes 4 Radiotherapy, Intensity-Modulated 3 130-nm albumin-bound paclitaxel 3 Radiotherapy 2 Fluorouracil 2 niraparib 1 irinotecan sucrosofate 1 folfirinox 1 durvalumab 1 dehydroftorafur 1 Surgical Procedures, Operative 1 S 1 (combination) 1 Resistance Training 1 Radiotherapy, Image-Guided 1 Radiosurgery 1 Panitumumab 1 Oxaliplatin 1 Optical Imaging 1 Nivolumab 1 Metformin 1 Losartan 1 Leucovorin 1 Irinotecan 1 Ipilimumab 1 Interleukin 1 Receptor Antagonist Protein 1 Folfox protocol 1 Ethiodized Oil 1 Electronic Health Records 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03404960 2025-10-10

Parpvax

University of Pennsylvania

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡